SCHEMBL4127985

SCHEMBL4127985

COC(=O)C=Cc1cccn1-c1c(F)cc(Cl)cc1C(=O)c1cccc(OC)c1OC

nearest known ligand 0.36

Predicted protein targets (top 19)

geneUniProtsupporting neighboursconfidence
RAB9A P51151 3/20 0.36
SMN1; SMN2 Q16637 3/20 0.36
NPC1 O15118 2/20 0.36
KDM4E B2RXH2 2/20 0.36
ALDH1A1 P00352 2/20 0.36
LMNA P02545 1/20 0.36
NPSR1 Q6W5P4 1/20 0.36
BCHE P06276 1/20 0.36
DRD3 P35462 2/20 0.35
NFE2L2 Q16236 2/20 0.34
KRAS P01116 2/20 0.34
TP53 P04637 1/20 0.34
MEN1 O00255 1/20 0.34
KMT2A Q03164 1/20 0.34
MCL1 Q07820 1/20 0.34
TUBB1 Q9H4B7 1/20 0.33
GAA P10253 1/20 0.33
MAPK14 Q16539 1/20 0.33
CYP3A4 P08684 1/20 0.33

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4127982 1.00 RAB9A (0.36) RAB9ASMN1; SMN2NPC1KDM4EALDH1A1
SCHEMBL4133226 0.89 GAA (0.45) RAB9ASMN1; SMN2NPC1KDM4EALDH1A1
SCHEMBL13775239 0.86 NFE2L2 (0.38) RAB9ASMN1; SMN2NPC1KDM4EALDH1A1
SCHEMBL13775255 0.83 CYP3A4 (0.36) RAB9ASMN1; SMN2NPC1KDM4EALDH1A1
SCHEMBL4128321 0.82 ALDH1A1 (0.35) KDM4EALDH1A1BCHENFE2L2KRAS
SCHEMBL4128318 0.82 ALDH1A1 (0.35) KDM4EALDH1A1BCHENFE2L2KRAS
SCHEMBL13775456 0.80 NR1H4 (0.37) KDM4EKMT2AGAA
SCHEMBL4110282 0.79 RAB9A (0.41) RAB9ASMN1; SMN2NPC1KDM4EALDH1A1
SCHEMBL4123573 0.79 NR1H4 (0.36) SMN1; SMN2LMNANFE2L2TP53MEN1
SCHEMBL4123566 0.79 NR1H4 (0.36) SMN1; SMN2LMNANFE2L2TP53MEN1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20090181942-A1 TRICYCLIC COMPOUNDS DAIICHI SANKYO COMPANY, LIMITED (JP) 2009-07-16 US disclosed
EP-1939205-A1 TRICYCLIC COMPOUND Daiichi Sankyo Company, Limited (JP) 2008-07-02 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090181942-A1 TRICYCLIC COMPOUNDS FDFT1, COASY, HMGCR RAB9A 4041/4885SMN1; SMN2 4445/4885NPC1 187/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.